Botulinum Toxin Market By Product (Botulinum Toxin Type A, Botulinum Toxin Type B), By Application (Aesthetic, Therapeutic), By End User (Hospitals, Specialty and Dermatology Clinics, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031

Botulinum Toxin Market

Botulinum toxin, also called as “miracle poison,” is one of the most poisonous biological substances. It is a neurotoxin produced by the bacterium Clostridium botulinum, an anaerobic, gram-positive, spore-forming rod commonly found on plants, in soil, water and the intestinal tracts of animals. Botulinum toxin induces weakness of striated muscles by inhibiting transmission of alpha motor neurons at the neuromuscular junction. This has led to its use in conditions with muscular overactivity, such as dystonia. Transmission is also inhibited at gamma neurons in muscle spindles, which may alter reflex overactivity. The toxin also inhibits release of acetylcholine in all parasympathetic and cholinergic postganglionic sympathetic neurons. This has generated interest in its use as a treatment for overactive smooth muscles (for example, in achalasia) or abnormal activity of glands (for example, hyperhidrosis).

The key factors that drive the growth of the botulinum toxin market size include increase in geriatric population, rise in number of licensed medical centers, and surge in self-awareness among population regarding the physical appearance. Moreover, the increase in usage of botulinum toxin injection in several aesthetic procedures including the treatment of glabellar lines, chemical browlift, and forehead lines are some of the major botulinum toxin market trends. However, side effects associated with botulinum toxin procedures and high cost of procedures are likely to hamper the growth of the market during the forecast period. Conversely, rise in investment in R&D activities by major manufacturers to explore the therapeutic use of botulinum toxin are expected to provide numerous opportunities for market growth during the forecast period.

By product, the botulinum toxin A segment dominated the botulinum toxin industry in 2021 and is expected to remain dominant during the forecast period, owing to rise in customer preference due to advantages including minimal pain, no blood loss, and lack of scarring during the procedure. In addition, Botulinum toxin type-A has been increasingly utilized to treat chronic migraine, tension-type headache, and other primary neurological disorders which further propel the market growth.

By application, the therapeutic segment dominated the market in 2021 and is expected to remain dominant during the forecast period, owing to heavy investment for extensive R&D of therapeutics products and its expanding applications in various disease categories such as chronic migraine, conditions such as hyperhidrosis, and over-reactive bladders.

By end user, the specialty and dermatology clinic segment dominated the botulinum toxin Industry in 2021 and is expected to remain dominant during the forecast period, owing to increase in number of dermatology and rise in expenditure by governments to improve the healthcare industry. Moreover, higher number of non-invasive cosmetic procedures performed in the specialty and dermatology clinics as compared to hospitals which further drives the segment growth.

Region wise, North America has the highest botulinum toxin market share and registered a significant CAGR during the forecast period. The dominance is due to higher number of botulinum toxin procedures, increase in number of approvals for aesthetic products, a strong presence of key players, and advancements in medical and aesthetic sector. Asia-Pacific is projected to register the highest CAGR during the botulinum toxin market forecast. Increase in geriatric population, rise in awareness among young population regarding aesthetics, growth in healthcare expenditures, and surge in adoption of Botox products are the key driving factors that boost the growth of the market in the region.

KEY FINDINGS OF STUDY

 On the basis of botulinum toxin market analysis, the botulinum toxin type A segment dominated the market in 2021 and is expected to continue this trend during the forecast period.

On the basis of application, the therapeutic segment dominated the market in 2021, and is expected to continue this trend during the forecast period.

On the basis of end user, specialty and dermatology clinic segment is projected to grow at a higher CAGR during the forecast period.

On the basis of region, North America held the largest botulinum toxin market share in 2021. However, Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.

 

Overview

The global Botulinum toxin market accounted for $5814.9 million in 2021, and is expected to reach $13132.72 million by 2031, registering a CAGR of 8.6% from 2022 to 2031.

Botulinum toxin, one of the most poisonous biological substances known, and is a neurotoxin produced by the bacterium Clostridium botulinum. C. Botulinum elaborates eight antigenically distinguishable exotoxins (A, B, C1, C2, D, E, F and G). All serotypes interfere with neural transmission by blocking the release of acetylcholine, the principal neurotransmitter at the neuromuscular junction, causing muscle paralysis. The weakness induced by injection with botulinum toxin A usually lasts about three months.

Botulinum toxins now play a significant role in the management of a wide variety of medical conditions, especially strabismus and focal dystonia and some chronic conditions that respond only partially to medical treatment. The list of possible new indications is rapidly expanding. The aesthetic applications include correction of lines, creases and wrinkling all over the face, chin, neck, and chest to dermatological applications such as hyperhidrosis. Injections with botulinum toxin are generally well tolerated and side effects are few. A precise knowledge and understanding of the functional anatomy of the mimetic muscles is necessary to correctly use botulinum toxins in clinical practice.

The botulinum toxin market is expected to experience significant growth during the forecast period owing to surge in demand for cosmetic non-invasive surgical procedures, new product launches, increase in affordability and amendments in reimbursement policies to cover botulinum injections. In addition, rise in number of botulinum toxin procedure further facilitates the growth of the market. However, side effects associated with Botox procedures and high cost of these procedures are expected to impede the market growth in emerging region. In contrast, rise in investment in R&D activities by major manufacturers to explore the therapeutic use of botulinum toxin are anticipated to provide significant growth opportunities for the botulinum toxin market.

The Botulinum toxin market is segmented on the basis of product, application, end user and region. On the basis of product, the market is classified into botulinum toxin type A and botulinum toxin type B. On the basis of application, the market is divided into aesthetic and therapeutic. On the basis of end user, the market is classified into hospitals, specialty & dermatology clinics and others.

Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

The report provides a comprehensive analysis of the key players that operate in the global botulinum toxin market. The key companies profiled in the report include Merz Pharma GmbH And Co. Kgaa, Abbvie Inc (Allergan), Ipsen Group, Revance Therapeutics Inc, Medy-Tox, Inc., Hugel, Inc., Galderma, Us Worldmed, Llc ,Evolus Inc., and Daewoong Pharmaceutical.

Key Benefits For Stakeholders

●This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the botulinum toxin market analysis from 2021 to 2031 to identify the prevailing botulinum toxin market opportunities.

●The market research is offered along with information related to key drivers, restraints, and opportunities.

●Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

●In-depth analysis of the botulinum toxin market segmentation assists to determine the prevailing market opportunities.

●Major countries in each region are mapped according to their revenue contribution to the global market.

●Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

●The report includes the analysis of the regional as well as global botulinum toxin market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

○ EVOLUS INC

Scope of Botulinum Toxin Market Report

1.1.Report description

1.2.Key market segments

1.3.Key benefits to the stakeholders

1.4.Research Methodology

1.4.1.Secondary research

1.4.2.Primary research

1.4.3.Analyst tools and models

2.1.Key findings of the study

2.2.CXO Perspective

3.1.Market definition and scope

3.2.Key findings

3.2.1.Top investment pockets

3.3.Porter’s five forces analysis

3.4.Top player positioning

3.5.Market dynamics

3.5.1.Drivers

3.5.2.Restraints

3.5.3.Opportunities

3.6.COVID-19 Impact Analysis on the market

4.1 Overview

4.1.1 Market size and forecast

4.2 Botulinum Toxin Type A

4.2.1 Key market trends, growth factors and opportunities

4.2.2 Market size and forecast, by region

4.2.3 Market share analysis by country

4.3 Botulinum Toxin Type B

4.3.1 Key market trends, growth factors and opportunities

4.3.2 Market size and forecast, by region

4.3.3 Market share analysis by country

5.1 Overview

5.1.1 Market size and forecast

5.2 Aesthetic

5.2.1 Key market trends, growth factors and opportunities

5.2.2 Market size and forecast, by region

5.2.3 Market share analysis by country

5.3 Therapeutic

5.3.1 Key market trends, growth factors and opportunities

5.3.2 Market size and forecast, by region

5.3.3 Market share analysis by country

6.1 Overview

6.1.1 Market size and forecast

6.2 Hospitals

6.2.1 Key market trends, growth factors and opportunities

6.2.2 Market size and forecast, by region

6.2.3 Market share analysis by country

6.3 Specialty and Dermatology Clinics

6.3.1 Key market trends, growth factors and opportunities

6.3.2 Market size and forecast, by region

6.3.3 Market share analysis by country

6.4 Others

6.4.1 Key market trends, growth factors and opportunities

6.4.2 Market size and forecast, by region

6.4.3 Market share analysis by country

7.1 Overview

7.1.1 Market size and forecast

7.2 North America

7.2.1 Key trends and opportunities

7.2.2 North America Market size and forecast, by Product

7.2.3 North America Market size and forecast, by Application

7.2.4 North America Market size and forecast, by End User

7.2.5 North America Market size and forecast, by country

7.2.5.1 U.S.

7.2.5.1.1 Key market trends, growth factors and opportunities

7.2.5.1.2 Market size and forecast, by Product

7.2.5.1.3 Market size and forecast, by Application

7.2.5.1.4 Market size and forecast, by End User

7.2.5.2 Canada

7.2.5.2.1 Key market trends, growth factors and opportunities

7.2.5.2.2 Market size and forecast, by Product

7.2.5.2.3 Market size and forecast, by Application

7.2.5.2.4 Market size and forecast, by End User

7.2.5.3 Mexico

7.2.5.3.1 Key market trends, growth factors and opportunities

7.2.5.3.2 Market size and forecast, by Product

7.2.5.3.3 Market size and forecast, by Application

7.2.5.3.4 Market size and forecast, by End User

7.3 Europe

7.3.1 Key trends and opportunities

7.3.2 Europe Market size and forecast, by Product

7.3.3 Europe Market size and forecast, by Application

7.3.4 Europe Market size and forecast, by End User

7.3.5 Europe Market size and forecast, by country

7.3.5.1 Germany

7.3.5.1.1 Key market trends, growth factors and opportunities

7.3.5.1.2 Market size and forecast, by Product

7.3.5.1.3 Market size and forecast, by Application

7.3.5.1.4 Market size and forecast, by End User

7.3.5.2 France

7.3.5.2.1 Key market trends, growth factors and opportunities

7.3.5.2.2 Market size and forecast, by Product

7.3.5.2.3 Market size and forecast, by Application

7.3.5.2.4 Market size and forecast, by End User

7.3.5.3 UK

7.3.5.3.1 Key market trends, growth factors and opportunities

7.3.5.3.2 Market size and forecast, by Product

7.3.5.3.3 Market size and forecast, by Application

7.3.5.3.4 Market size and forecast, by End User

7.3.5.4 Italy

7.3.5.4.1 Key market trends, growth factors and opportunities

7.3.5.4.2 Market size and forecast, by Product

7.3.5.4.3 Market size and forecast, by Application

7.3.5.4.4 Market size and forecast, by End User

7.3.5.5 Spain

7.3.5.5.1 Key market trends, growth factors and opportunities

7.3.5.5.2 Market size and forecast, by Product

7.3.5.5.3 Market size and forecast, by Application

7.3.5.5.4 Market size and forecast, by End User

7.3.5.6 Rest of Europe

7.3.5.6.1 Key market trends, growth factors and opportunities

7.3.5.6.2 Market size and forecast, by Product

7.3.5.6.3 Market size and forecast, by Application

7.3.5.6.4 Market size and forecast, by End User

7.4 Asia-Pacific

7.4.1 Key trends and opportunities

7.4.2 Asia-Pacific Market size and forecast, by Product

7.4.3 Asia-Pacific Market size and forecast, by Application

7.4.4 Asia-Pacific Market size and forecast, by End User

7.4.5 Asia-Pacific Market size and forecast, by country

7.4.5.1 Japan

7.4.5.1.1 Key market trends, growth factors and opportunities

7.4.5.1.2 Market size and forecast, by Product

7.4.5.1.3 Market size and forecast, by Application

7.4.5.1.4 Market size and forecast, by End User

7.4.5.2 China

7.4.5.2.1 Key market trends, growth factors and opportunities

7.4.5.2.2 Market size and forecast, by Product

7.4.5.2.3 Market size and forecast, by Application

7.4.5.2.4 Market size and forecast, by End User

7.4.5.3 Australia

7.4.5.3.1 Key market trends, growth factors and opportunities

7.4.5.3.2 Market size and forecast, by Product

7.4.5.3.3 Market size and forecast, by Application

7.4.5.3.4 Market size and forecast, by End User

7.4.5.4 India

7.4.5.4.1 Key market trends, growth factors and opportunities

7.4.5.4.2 Market size and forecast, by Product

7.4.5.4.3 Market size and forecast, by Application

7.4.5.4.4 Market size and forecast, by End User

7.4.5.5 South Korea

7.4.5.5.1 Key market trends, growth factors and opportunities

7.4.5.5.2 Market size and forecast, by Product

7.4.5.5.3 Market size and forecast, by Application

7.4.5.5.4 Market size and forecast, by End User

7.4.5.6 Rest of Asia-Pacific

7.4.5.6.1 Key market trends, growth factors and opportunities

7.4.5.6.2 Market size and forecast, by Product

7.4.5.6.3 Market size and forecast, by Application

7.4.5.6.4 Market size and forecast, by End User

7.5 LAMEA

7.5.1 Key trends and opportunities

7.5.2 LAMEA Market size and forecast, by Product

7.5.3 LAMEA Market size and forecast, by Application

7.5.4 LAMEA Market size and forecast, by End User

7.5.5 LAMEA Market size and forecast, by country

7.5.5.1 Brazil

7.5.5.1.1 Key market trends, growth factors and opportunities

7.5.5.1.2 Market size and forecast, by Product

7.5.5.1.3 Market size and forecast, by Application

7.5.5.1.4 Market size and forecast, by End User

7.5.5.2 Saudi Arabia

7.5.5.2.1 Key market trends, growth factors and opportunities

7.5.5.2.2 Market size and forecast, by Product

7.5.5.2.3 Market size and forecast, by Application

7.5.5.2.4 Market size and forecast, by End User

7.5.5.3 South Africa

7.5.5.3.1 Key market trends, growth factors and opportunities

7.5.5.3.2 Market size and forecast, by Product

7.5.5.3.3 Market size and forecast, by Application

7.5.5.3.4 Market size and forecast, by End User

7.5.5.4 Rest of LAMEA

7.5.5.4.1 Key market trends, growth factors and opportunities

7.5.5.4.2 Market size and forecast, by Product

7.5.5.4.3 Market size and forecast, by Application

7.5.5.4.4 Market size and forecast, by End User

8.1. Introduction

8.2. Top winning strategies

8.3. Product Mapping of Top 10 Player

8.4. Competitive Dashboard

8.5. Competitive Heatmap

8.6. Key developments

9.1 REVANCE THERAPEUTICS INC

9.1.1 Company overview

9.1.2 Company snapshot

9.1.3 Operating business segments

9.1.4 Product portfolio

9.1.5 Business performance

9.1.6 Key strategic moves and developments

9.2 Medy-Tox, Inc.

9.2.1 Company overview

9.2.2 Company snapshot

9.2.3 Operating business segments

9.2.4 Product portfolio

9.2.5 Business performance

9.2.6 Key strategic moves and developments

9.3 galderma

9.3.1 Company overview

9.3.2 Company snapshot

9.3.3 Operating business segments

9.3.4 Product portfolio

9.3.5 Business performance

9.3.6 Key strategic moves and developments

9.4 US WORLDMED, LLC

9.4.1 Company overview

9.4.2 Company snapshot

9.4.3 Operating business segments

9.4.4 Product portfolio

9.4.5 Business performance

9.4.6 Key strategic moves and developments

9.5 Abbvie Inc (Allergan)

9.5.1 Company overview

9.5.2 Company snapshot

9.5.3 Operating business segments

9.5.4 Product portfolio

9.5.5 Business performance

9.5.6 Key strategic moves and developments

9.6 DAEWOONG PHARMACEUTICAL

9.6.1 Company overview

9.6.2 Company snapshot

9.6.3 Operating business segments

9.6.4 Product portfolio

9.6.5 Business performance

9.6.6 Key strategic moves and developments

9.7 Ipsen Group

9.7.1 Company overview

9.7.2 Company snapshot

9.7.3 Operating business segments

9.7.4 Product portfolio

9.7.5 Business performance

9.7.6 Key strategic moves and developments

9.8 MERZ PHARMA GMBH AND CO. KGAA

9.8.1 Company overview

9.8.2 Company snapshot

9.8.3 Operating business segments

9.8.4 Product portfolio

9.8.5 Business performance

9.8.6 Key strategic moves and developments

9.9 HUGEL, INC.

9.9.1 Company overview

9.9.2 Company snapshot

9.9.3 Operating business segments

9.9.4 Product portfolio

9.9.5 Business performance

9.9.6 Key strategic moves and developments

9.10 EVOLUS INC.

9.10.1 Company overview

9.10.2 Company snapshot

9.10.3 Operating business segments

9.10.4 Product portfolio

9.10.5 Business performance

9.10.6 Key strategic moves and development

LIST OF TABLES

TABLE 1. GLOBAL BOTULINUM TOXIN MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)

TABLE 2. BOTULINUM TOXIN MARKET FOR BOTULINUM TOXIN TYPE A, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 3. BOTULINUM TOXIN MARKET FOR BOTULINUM TOXIN TYPE A, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 4. BOTULINUM TOXIN MARKET FOR BOTULINUM TOXIN TYPE B, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 5. BOTULINUM TOXIN MARKET FOR BOTULINUM TOXIN TYPE B, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 6. GLOBAL BOTULINUM TOXIN MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 7. BOTULINUM TOXIN MARKET FOR AESTHETIC, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 8. BOTULINUM TOXIN MARKET FOR AESTHETIC, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 9. BOTULINUM TOXIN MARKET FOR THERAPEUTIC, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 10. BOTULINUM TOXIN MARKET FOR THERAPEUTIC, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 11. GLOBAL BOTULINUM TOXIN MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 12. BOTULINUM TOXIN MARKET FOR HOSPITALS, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 13. BOTULINUM TOXIN MARKET FOR HOSPITALS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 14. BOTULINUM TOXIN MARKET FOR SPECIALTY AND DERMATOLOGY CLINICS, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 15. BOTULINUM TOXIN MARKET FOR SPECIALTY AND DERMATOLOGY CLINICS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 16. BOTULINUM TOXIN MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 17. BOTULINUM TOXIN MARKET FOR OTHERS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 18. BOTULINUM TOXIN MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 19. NORTH AMERICA BOTULINUM TOXIN MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)

TABLE 20. NORTH AMERICA BOTULINUM TOXIN MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 21. NORTH AMERICA BOTULINUM TOXIN MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 22. NORTH AMERICA BOTULINUM TOXIN MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 23. U.S. BOTULINUM TOXIN MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)

TABLE 24. U.S. BOTULINUM TOXIN MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 25. U.S. BOTULINUM TOXIN MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 26. CANADA BOTULINUM TOXIN MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)

TABLE 27. CANADA BOTULINUM TOXIN MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 28. CANADA BOTULINUM TOXIN MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 29. MEXICO BOTULINUM TOXIN MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)

TABLE 30. MEXICO BOTULINUM TOXIN MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 31. MEXICO BOTULINUM TOXIN MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 32. EUROPE BOTULINUM TOXIN MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)

TABLE 33. EUROPE BOTULINUM TOXIN MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 34. EUROPE BOTULINUM TOXIN MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 35. EUROPE BOTULINUM TOXIN MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 36. GERMANY BOTULINUM TOXIN MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)

TABLE 37. GERMANY BOTULINUM TOXIN MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 38. GERMANY BOTULINUM TOXIN MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 39. FRANCE BOTULINUM TOXIN MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)

TABLE 40. FRANCE BOTULINUM TOXIN MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 41. FRANCE BOTULINUM TOXIN MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 42. UK BOTULINUM TOXIN MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)

TABLE 43. UK BOTULINUM TOXIN MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 44. UK BOTULINUM TOXIN MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 45. ITALY BOTULINUM TOXIN MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)

TABLE 46. ITALY BOTULINUM TOXIN MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 47. ITALY BOTULINUM TOXIN MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 48. SPAIN BOTULINUM TOXIN MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)

TABLE 49. SPAIN BOTULINUM TOXIN MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 50. SPAIN BOTULINUM TOXIN MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 51. REST OF EUROPE BOTULINUM TOXIN MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)

TABLE 52. REST OF EUROPE BOTULINUM TOXIN MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 53. REST OF EUROPE BOTULINUM TOXIN MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 54. ASIA-PACIFIC BOTULINUM TOXIN MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)

TABLE 55. ASIA-PACIFIC BOTULINUM TOXIN MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 56. ASIA-PACIFIC BOTULINUM TOXIN MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 57. ASIA-PACIFIC BOTULINUM TOXIN MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 58. JAPAN BOTULINUM TOXIN MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)

TABLE 59. JAPAN BOTULINUM TOXIN MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 60. JAPAN BOTULINUM TOXIN MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 61. CHINA BOTULINUM TOXIN MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)

TABLE 62. CHINA BOTULINUM TOXIN MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 63. CHINA BOTULINUM TOXIN MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 64. AUSTRALIA BOTULINUM TOXIN MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)

TABLE 65. AUSTRALIA BOTULINUM TOXIN MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 66. AUSTRALIA BOTULINUM TOXIN MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 67. INDIA BOTULINUM TOXIN MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)

TABLE 68. INDIA BOTULINUM TOXIN MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 69. INDIA BOTULINUM TOXIN MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 70. SOUTH KOREA BOTULINUM TOXIN MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)

TABLE 71. SOUTH KOREA BOTULINUM TOXIN MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 72. SOUTH KOREA BOTULINUM TOXIN MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 73. REST OF ASIA-PACIFIC BOTULINUM TOXIN MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)

TABLE 74. REST OF ASIA-PACIFIC BOTULINUM TOXIN MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 75. REST OF ASIA-PACIFIC BOTULINUM TOXIN MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 76. LAMEA BOTULINUM TOXIN MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)

TABLE 77. LAMEA BOTULINUM TOXIN MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 78. LAMEA BOTULINUM TOXIN MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 79. LAMEA BOTULINUM TOXIN MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 80. BRAZIL BOTULINUM TOXIN MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)

TABLE 81. BRAZIL BOTULINUM TOXIN MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 82. BRAZIL BOTULINUM TOXIN MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 83. SAUDI ARABIA BOTULINUM TOXIN MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)

TABLE 84. SAUDI ARABIA BOTULINUM TOXIN MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 85. SAUDI ARABIA BOTULINUM TOXIN MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 86. SOUTH AFRICA BOTULINUM TOXIN MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)

TABLE 87. SOUTH AFRICA BOTULINUM TOXIN MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 88. SOUTH AFRICA BOTULINUM TOXIN MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 89. REST OF LAMEA BOTULINUM TOXIN MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)

TABLE 90. REST OF LAMEA BOTULINUM TOXIN MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)

TABLE 91. REST OF LAMEA BOTULINUM TOXIN MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 92.REVANCE THERAPEUTICS INC: COMPANY SNAPSHOT

TABLE 93.REVANCE THERAPEUTICS INC: OPERATING SEGMENTS

TABLE 94.REVANCE THERAPEUTICS INC: PRODUCT PORTFOLIO

TABLE 95.REVANCE THERAPEUTICS INC: NET SALES

TABLE 96.REVANCE THERAPEUTICS INC: KEY STRATERGIES

TABLE 97.MEDY-TOX, INC.: COMPANY SNAPSHOT

TABLE 98.MEDY-TOX, INC.: OPERATING SEGMENTS

TABLE 99.MEDY-TOX, INC.: PRODUCT PORTFOLIO

TABLE 100.MEDY-TOX, INC.: NET SALES

TABLE 101.MEDY-TOX, INC.: KEY STRATERGIES

TABLE 102.GALDERMA: COMPANY SNAPSHOT

TABLE 103.GALDERMA: OPERATING SEGMENTS

TABLE 104.GALDERMA: PRODUCT PORTFOLIO

TABLE 105.GALDERMA: NET SALES

TABLE 106.GALDERMA: KEY STRATERGIES

TABLE 107.US WORLDMED, LLC: COMPANY SNAPSHOT

TABLE 108.US WORLDMED, LLC: OPERATING SEGMENTS

TABLE 109.US WORLDMED, LLC: PRODUCT PORTFOLIO

TABLE 110.US WORLDMED, LLC: NET SALES

TABLE 111.US WORLDMED, LLC: KEY STRATERGIES

TABLE 112.ABBVIE INC (ALLERGAN): COMPANY SNAPSHOT

TABLE 113.ABBVIE INC (ALLERGAN): OPERATING SEGMENTS

TABLE 114.ABBVIE INC (ALLERGAN): PRODUCT PORTFOLIO

TABLE 115.ABBVIE INC (ALLERGAN): NET SALES

TABLE 116.ABBVIE INC (ALLERGAN): KEY STRATERGIES

TABLE 117.DAEWOONG PHARMACEUTICAL: COMPANY SNAPSHOT

TABLE 118.DAEWOONG PHARMACEUTICAL: OPERATING SEGMENTS

TABLE 119.DAEWOONG PHARMACEUTICAL: PRODUCT PORTFOLIO

TABLE 120.DAEWOONG PHARMACEUTICAL: NET SALES

TABLE 121.DAEWOONG PHARMACEUTICAL: KEY STRATERGIES

TABLE 122.IPSEN GROUP: COMPANY SNAPSHOT

TABLE 123.IPSEN GROUP: OPERATING SEGMENTS

TABLE 124.IPSEN GROUP: PRODUCT PORTFOLIO

TABLE 125.IPSEN GROUP: NET SALES

TABLE 126.IPSEN GROUP: KEY STRATERGIES

TABLE 127.MERZ PHARMA GMBH AND CO. KGAA: COMPANY SNAPSHOT

TABLE 128.MERZ PHARMA GMBH AND CO. KGAA: OPERATING SEGMENTS

TABLE 129.MERZ PHARMA GMBH AND CO. KGAA: PRODUCT PORTFOLIO

TABLE 130.MERZ PHARMA GMBH AND CO. KGAA: NET SALES

TABLE 131.MERZ PHARMA GMBH AND CO. KGAA: KEY STRATERGIES

TABLE 132.HUGEL, INC.: COMPANY SNAPSHOT

TABLE 133.HUGEL, INC.: OPERATING SEGMENTS

TABLE 134.HUGEL, INC.: PRODUCT PORTFOLIO

TABLE 135.HUGEL, INC.: NET SALES

TABLE 136.HUGEL, INC.: KEY STRATERGIES

TABLE 137.EVOLUS INC.: COMPANY SNAPSHOT

TABLE 138.EVOLUS INC.: OPERATING SEGMENTS

TABLE 139.EVOLUS INC.: PRODUCT PORTFOLIO

TABLE 140.EVOLUS INC.: NET SALES

TABLE 141.EVOLUS INC.: KEY STRATERGIES LIST OF FIGURES

FIGURE 1.BOTULINUM TOXIN MARKET SEGMENTATION

FIGURE 2.BOTULINUM TOXIN MARKET,2021-2031

FIGURE 3.BOTULINUM TOXIN MARKET,2021-2031

FIGURE 4. TOP INVESTMENT POCKETS, BY REGION

FIGURE 5.PORTER FIVE-1

FIGURE 6.PORTER FIVE-2

FIGURE 7.PORTER FIVE-3

FIGURE 8.PORTER FIVE-4

FIGURE 9.PORTER FIVE-5

FIGURE 10.TOP PLAYER POSITIONING

FIGURE 11.BOTULINUM TOXIN MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES

FIGURE 12.BOTULINUM TOXIN MARKET,BY PRODUCT,2021(%)

FIGURE 13.COMPARATIVE SHARE ANALYSIS OF BOTULINUM TOXIN TYPE A BOTULINUM TOXIN MARKET,2021-2031(%)

FIGURE 14.COMPARATIVE SHARE ANALYSIS OF BOTULINUM TOXIN TYPE B BOTULINUM TOXIN MARKET,2021-2031(%)

FIGURE 15.BOTULINUM TOXIN MARKET,BY APPLICATION,2021(%)

FIGURE 16.COMPARATIVE SHARE ANALYSIS OF AESTHETIC BOTULINUM TOXIN MARKET,2021-2031(%)

FIGURE 17.COMPARATIVE SHARE ANALYSIS OF THERAPEUTIC BOTULINUM TOXIN MARKET,2021-2031(%)

FIGURE 18.BOTULINUM TOXIN MARKET,BY END USER,2021(%)

FIGURE 19.COMPARATIVE SHARE ANALYSIS OF HOSPITALS BOTULINUM TOXIN MARKET,2021-2031(%)

FIGURE 20.COMPARATIVE SHARE ANALYSIS OF SPECIALTY AND DERMATOLOGY CLINICS BOTULINUM TOXIN MARKET,2021-2031(%)

FIGURE 21.COMPARATIVE SHARE ANALYSIS OF OTHERS BOTULINUM TOXIN MARKET,2021-2031(%)

FIGURE 22.BOTULINUM TOXIN MARKET BY REGION,2021

FIGURE 23.U.S. BOTULINUM TOXIN MARKET,2021-2031($MILLION)

FIGURE 24.CANADA BOTULINUM TOXIN MARKET,2021-2031($MILLION)

FIGURE 25.MEXICO BOTULINUM TOXIN MARKET,2021-2031($MILLION)

FIGURE 26.GERMANY BOTULINUM TOXIN MARKET,2021-2031($MILLION)

FIGURE 27.FRANCE BOTULINUM TOXIN MARKET,2021-2031($MILLION)

FIGURE 28.UK BOTULINUM TOXIN MARKET,2021-2031($MILLION)

FIGURE 29.ITALY BOTULINUM TOXIN MARKET,2021-2031($MILLION)

FIGURE 30.SPAIN BOTULINUM TOXIN MARKET,2021-2031($MILLION)

FIGURE 31.REST OF EUROPE BOTULINUM TOXIN MARKET,2021-2031($MILLION)

FIGURE 32.JAPAN BOTULINUM TOXIN MARKET,2021-2031($MILLION)

FIGURE 33.CHINA BOTULINUM TOXIN MARKET,2021-2031($MILLION)

FIGURE 34.AUSTRALIA BOTULINUM TOXIN MARKET,2021-2031($MILLION)

FIGURE 35.INDIA BOTULINUM TOXIN MARKET,2021-2031($MILLION)

FIGURE 36.SOUTH KOREA BOTULINUM TOXIN MARKET,2021-2031($MILLION)

FIGURE 37.REST OF ASIA-PACIFIC BOTULINUM TOXIN MARKET,2021-2031($MILLION)

FIGURE 38.BRAZIL BOTULINUM TOXIN MARKET,2021-2031($MILLION)

FIGURE 39.SAUDI ARABIA BOTULINUM TOXIN MARKET,2021-2031($MILLION)

FIGURE 40.SOUTH AFRICA BOTULINUM TOXIN MARKET,2021-2031($MILLION)

FIGURE 41.REST OF LAMEA BOTULINUM TOXIN MARKET,2021-2031($MILLION)

FIGURE 42. TOP WINNING STRATEGIES, BY YEAR

FIGURE 43. TOP WINNING STRATEGIES, BY DEVELOPMENT

FIGURE 44. TOP WINNING STRATEGIES, BY COMPANY

FIGURE 45.PRODUCT MAPPING OF TOP 10 PLAYERS

FIGURE 46.COMPETITIVE DASHBOARD

FIGURE 47.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS

FIGURE 48.REVANCE THERAPEUTICS INC.: NET SALES ($MILLION)

FIGURE 49.MEDY-TOX, INC..: NET SALES ($MILLION)

FIGURE 50.GALDERMA.: NET SALES ($MILLION)

FIGURE 51.US WORLDMED, LLC.: NET SALES ($MILLION)

FIGURE 52.ABBVIE INC (ALLERGAN).: NET SALES ($MILLION)

FIGURE 53.DAEWOONG PHARMACEUTICAL.: NET SALES ($MILLION)

FIGURE 54.IPSEN GROUP.: NET SALES ($MILLION)

FIGURE 55.MERZ PHARMA GMBH AND CO. KGAA.: NET SALES ($MILLION)

FIGURE 56.HUGEL, INC..: NET SALES ($MILLION)

FIGURE 57.EVOLUS INC..: NET SALES ($MILLION